Business Context and Reporting Period
This Form 6-K filing by Galmed Pharmaceuticals Ltd. is dated August 27, 2024. The report announces a corporate action regarding the Company's capital structure rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital adjustments.
Material Changes
The Company announced a reverse share split to be effected after market close on August 29, 2024, at a ratio of 1-for-12. Key details include:
- Split Ratio: 12 ordinary shares (par value NIS 0.15) consolidate into 1 ordinary share (par value NIS 1.80).
- Trading Resumption: Trading on the Nasdaq Capital Market will resume on August 30, 2024.
- Authorized Capital: Post-split authorized share capital will be 1,666,667 ordinary shares.
- Outstanding Shares: Approximately 632,889 ordinary shares will be issued and outstanding.
- Fractional Shares: No fractional shares will be issued; all will be rounded up to the nearest whole share.
- Options Adjustment: A proportionate adjustment will be made to the exercise price and number of shares for all outstanding options.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, specific risks, or contingencies beyond the mechanics of the reverse split. The document notes that this Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the exact number of shares held post-split, accounting for the rounding up of fractional shares.
- Confirm the adjusted exercise price and share count for any outstanding stock options.
- Monitor the stock price performance on the Nasdaq Capital Market starting August 30, 2024.
- Review the updated authorized share capital limits in subsequent filings.